{
     "PMID": "25450465",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20150330",
     "LR": "20150209",
     "IS": "1090-2430 (Electronic) 0014-4886 (Linking)",
     "VI": "264",
     "DP": "2015 Feb",
     "TI": "WASP-1, a canonical Wnt signaling potentiator, rescues hippocampal synaptic impairments induced by Abeta oligomers.",
     "PG": "14-25",
     "LID": "10.1016/j.expneurol.2014.11.005 [doi] S0014-4886(14)00365-3 [pii]",
     "AB": "Amyloid-beta (Abeta) oligomers are a key factor in Alzheimer's disease (AD)-associated synaptic dysfunction. Abeta oligomers block the induction of hippocampal long-term potentiation (LTP) in rodents. The activation of Wnt signaling prevents Abeta oligomer-induced neurotoxic effects. The compound WASP-1 (Wnt-activating small molecule potentiator-1), has been described as a synergist of the ligand Wnt-3a, enhancing the activation of Wnt/beta-catenin signaling. Herein, we report that WASP-1 administration successfully rescued Abeta-induced synaptic impairments both in vitro and in vivo. The activation of canonical Wnt/beta-catenin signaling by WASP-1 increased synaptic transmission and rescued hippocampal LTP impairments induced by Abeta oligomers. Additionally, intra-hippocampal administration of WASP-1 to the double transgenic APPswe/PS1dE9 mouse model of AD prevented synaptic protein loss and reduced tau phosphorylation levels. Moreover, we found that WASP-1 blocked Abeta aggregation in vitro and reduced pathological tau phosphorylation in vivo. These results indicate that targeting canonical Wnt signaling with WASP-1 could have value for treating AD.",
     "CI": [
          "Copyright (c) 2014 Elsevier Inc. All rights reserved."
     ],
     "FAU": [
          "Vargas, Jessica Y",
          "Ahumada, Juan",
          "Arrazola, Macarena S",
          "Fuenzalida, Marco",
          "Inestrosa, Nibaldo C"
     ],
     "AU": [
          "Vargas JY",
          "Ahumada J",
          "Arrazola MS",
          "Fuenzalida M",
          "Inestrosa NC"
     ],
     "AD": "Centro de Envejecimiento y Regeneracion (CARE), Departamento de Biologia Celular y Molecular, Facultad de Ciencias Biologicas, P. Universidad Catolica de Chile, Santiago, Chile. Centro de Neurobiologia y Plasticidad Cerebral, Departamento de Fisiologia, Facultad de Ciencias, Universidad de Valparaiso, Valparaiso, Chile. Centro de Envejecimiento y Regeneracion (CARE), Departamento de Biologia Celular y Molecular, Facultad de Ciencias Biologicas, P. Universidad Catolica de Chile, Santiago, Chile. Centro de Neurobiologia y Plasticidad Cerebral, Departamento de Fisiologia, Facultad de Ciencias, Universidad de Valparaiso, Valparaiso, Chile. Electronic address: marco.fuenzalida@uv.cl. Centro de Envejecimiento y Regeneracion (CARE), Departamento de Biologia Celular y Molecular, Facultad de Ciencias Biologicas, P. Universidad Catolica de Chile, Santiago, Chile; Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, Australia; Centro de Excelencia de Biomedicina de Magallanes (CEBIMA), Universidad de Magallanes, Puerto Montt, Chile. Electronic address: ninestrosa@bio.puc.cl.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "DEP": "20141120",
     "PL": "United States",
     "TA": "Exp Neurol",
     "JT": "Experimental neurology",
     "JID": "0370712",
     "RN": [
          "0 (Amyloid beta-Peptides)",
          "0 (Amyloid beta-Protein Precursor)",
          "0 (CCN Intercellular Signaling Proteins)",
          "0 (PSEN1 protein, human)",
          "0 (Presenilin-1)",
          "0 (Proto-Oncogene Proteins)",
          "0 (WISP1 protein, human)"
     ],
     "SB": "IM",
     "MH": [
          "Amyloid beta-Peptides/toxicity",
          "Amyloid beta-Protein Precursor/genetics",
          "Animals",
          "CCN Intercellular Signaling Proteins/*therapeutic use",
          "Cells, Cultured",
          "Excitatory Postsynaptic Potentials/drug effects/genetics",
          "Gene Expression Regulation/drug effects/genetics",
          "Hippocampus/*drug effects/pathology/physiology",
          "Humans",
          "Male",
          "Mice",
          "Mice, Transgenic",
          "Neurons/*drug effects",
          "Neurotoxicity Syndromes/*drug therapy/etiology/genetics/*pathology",
          "Phosphorylation/drug effects/genetics",
          "Presenilin-1/genetics",
          "Proto-Oncogene Proteins/*therapeutic use",
          "Rats",
          "Signal Transduction/drug effects/genetics",
          "Synapses/*drug effects/genetics/physiology/ultrastructure",
          "Time Factors"
     ],
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "Alzheimer's disease",
          "Abeta oligomers",
          "Synaptic plasticity",
          "Synaptic proteins",
          "WASP-1",
          "Wnt signaling"
     ],
     "EDAT": "2014/12/03 06:00",
     "MHDA": "2015/03/31 06:00",
     "CRDT": [
          "2014/12/03 06:00"
     ],
     "PHST": [
          "2014/08/17 00:00 [received]",
          "2014/11/04 00:00 [revised]",
          "2014/11/10 00:00 [accepted]",
          "2014/12/03 06:00 [entrez]",
          "2014/12/03 06:00 [pubmed]",
          "2015/03/31 06:00 [medline]"
     ],
     "AID": [
          "S0014-4886(14)00365-3 [pii]",
          "10.1016/j.expneurol.2014.11.005 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Exp Neurol. 2015 Feb;264:14-25. doi: 10.1016/j.expneurol.2014.11.005. Epub 2014 Nov 20.",
     "term": "hippocampus"
}